Updates in the Treatment of Advanced/Recurrent Endometrial Cancer: Data from the NRG-GY018 Study

Video

Ramez Eskander, MD, presents data from the GY018 study investigating pembrolizumab versus placebo in addition to carboplatin/paclitaxel in patients with advanced/recurrent endometrial cancer.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Related Content
Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers

Russ Conroy
October 24th 2024
Article

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Uterine Transposition Surgery Improves QOL Through Fertility Preservation

Ariana Pelosci
October 8th 2024
Article

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

Michael Ganio, PharmD, MS, BCPS, FASHP;Brian Slomovitz, MD;Lucio Gordan, MD
September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

PAX8, a marker for aggressive disease in numerous cancer types, was more highly expressed in Black patients with uterine serous carcinoma.

Uterine Serous Carcinoma Tumors Appear More Aggressive in Black Populations

Roman Fabbricatore
August 23rd 2024
Article

PAX8, a marker for aggressive disease in numerous cancer types, was more highly expressed in Black patients with uterine serous carcinoma.

Data support subcutaneous envafolimab plus lenvatinib as a promising new therapy option in advanced endometrial cancer.

Envafolimab Combo Yields Enduring Responses in Advanced Endometrial Cancer

Dylann Cohn-Emery
June 3rd 2024
Article

Data support subcutaneous envafolimab plus lenvatinib as a promising new therapy option in advanced endometrial cancer.